Medical Scientist Training Program    Back to Main

Faculty Detail    
Campus Address KAUL 330 Zip 0021
Phone  (20-5) -915
Other websites

Faculty Appointment(s)
Appointment Type Department Division Rank
Primary  Genetics   Clinical Genetics Professor
Center  Civitan International Research Center  Civitan International Research Center Professor
Center  Comprehensive Cancer Center  Comprehensive Cancer Center Professor
Center  Ctr for Glial Bio in Med  Ctr for Glial Bio in Med Professor

Graduate Biomedical Sciences Affiliations
Genetics, Genomics and Bioinformatics 
Integrative Genetics Graduate Program 
Medical Scientist Training Program 
Neuroscience Graduate Program 

Biographical Sketch 
Dr. Messiaen is a graduate of the Institute for Psychosocial Education in Kortrijk, Belgium. She completed her MS and PhD degrees (Molecular biology and cancer) at the University of Ghent in Flanders, Belgium, and then joined the staff of the Center of Medical Genetics at Ghent University Hospital, where she directed the molecular diagnostic laboratory from 1991 to 2003. She joined UAB in summer 2003 where she directs the Medical Genomics Laboratory in the Department of Genetics.

Society Memberships
Organization Name Position Held Org Link
American College of Medical Genetics  FACMG   
American Society of Human Genetics  member   
European Society of Human Genetics  member   
Human Genome Variation Society   member   

Research/Clinical Interest
Molecular genetics testing in hereditary disorders; molecular dissection of the variant forms of NF1
My research is focused on the development and provision of comprehensive genetic tests for a number of rare and common genetic disorders. My laboratory currently offers molecular diagnostic testing for all forms of neurofibromatoses (NF1, NF2, schwannomatosis, spinal NF, NF-Noonan, segmental or mosaic NF), Legius syndrome, Tuberous Sclerosis, the ras-o-pathies, Von Hippel-Lindau disorder, PTEN—disorder, autosomal recessive polycystic kidney disease, and others. My research has a special focus on Neurofibromatosis type1 and phenotypically overlapping disorders including Legius syndrome. We are interested to fully explore the diverse spectrum of NF1 mutations. We explore NF1 genotype-phenotype correlations using several complementary approaches, including comparison of discrete phenotypic signs in unrelated patients carrying an identical NF1 mutation, characterization of cells/tissues affected in patients with mosaic or segmental NF, definition of the mutational spectrum in patients with variant forms of NF (spinal NF, Watson syndrome, NF-Noonan).

Selected Publications 
Publication PUBMEDID
Messiaen LM, Callens T, Mortier G, Beysen D, Vandenbroucke I, Van Roy N, Speleman F, De Paepe A. Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat. 2000;15(6):541-55.

Vandenbroucke I, Vandesompele J, De Paepe A, Messiaen L. Quantification of NF1 transcripts reveals novel highly expressed splice variants. FEBS Lett. 2002 Jul 3;522(1-3):71-6.
Vandenbroucke I, van Doorn R, Callens T, Cobben JM, Starink TM, Messiaen L. Genetic and clinical mosaicism in a patient with neurofibromatosis type 1. Hum Genet. 2004 Feb;114(3):284-90.

Vandenbroucke I, Van Oostveldt P, Coene E, De Paepe A, Messiaen L.
Neurofibromin is actively transported to the nucleus. FEBS Lett. 2004 Feb 27;560(1-3):98-102.
Zatkova A, Messiaen L, Vandenbroucke I, Wieser R, Fonatsch C, Krainer AR, Wimmer K. Disruption of exonic splicing enhancer elements is the principal cause of exon skipping associated with seven nonsense or missense alleles of NF1. Hum Mutat. 2004 Dec;24(6):491-501.
Messiaen LM, Wimmer K. Pitfalls of automated comparative sequence analysis as a single platform for routine clinical testing for NF1. J Med Genet. 2005 May;42(5):e25.  15863657 
Wimmer K, Yao S, Claes K, Kehrer-Sawatzki H, Tinschert S, De Raedt T, Legius E, Callens T, Beiglböck H, Maertens O, Messiaen L.
Spectrum of single- and multiexon NF1 copy number changes in a cohort of 1,100 unselected NF1 patients. Genes Chromosomes Cancer. 2006 Mar;45(3):265-76.
Maertens O, Brems H, Vandesompele J, De Raedt T, Heyns I, Rosenbaum T, De Schepper S, De Paepe A, Mortier G, Janssens S, Speleman F, Legius E, Messiaen L. Comprehensive NF1 screening on cultured Schwann cells from neurofibromas. Hum Mutat. 2006 Oct;27(10):1030-40.

Upadhyaya M, Huson SM, Davies M, Thomas N, Chuzhanova N, Giovannini S, Evans DG, Howard E, Kerr B, Griffiths S, Consoli C, Side L, Adams D, Pierpont M, Hachen R, Barnicoat A, Li H, Wallace P, Van Biervliet JP, Stevenson D, Viskochil D, Baralle D, Haan E, Riccardi V, Turnpenny P, Lazaro C, Messiaen L. An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation.
Am J Hum Genet. 2007 Jan;80(1):140-51.
Wimmer K, Roca X, Beiglböck H, Callens T, Etzler J, Rao AR, Krainer AR, Fonatsch C, Messiaen L. Extensive in silico analysis of NF1 splicing defects uncovers determinants for splicing outcome upon 5' splice-site disruption. Hum Mutat. 2007 Jun;28(6):599-612.  17311297 
Maertens O, De Schepper S, Vandesompele J, Brems H, Heyns I, Janssens S, Speleman F, Legius E, Messiaen L. Molecular dissection of isolated disease features in mosaic neurofibromatosis type 1. Am J Hum Genet. 2007 Aug;81(2):243-51.
Brems H, Chmara M, Sahbatou M, Denayer E, Taniguchi K, Kato R, Somers R, Messiaen L, De Schepper S, Fryns JP, Cools J, Marynen P, Thomas G, Yoshimura A, Legius E. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet. 2007 Sep;39(9):1120-6.
De Schepper S, Maertens O, Callens T, Naeyaert JM, Lambert J, Messiaen L. Somatic mutation analysis in NF1 café au lait spots reveals two NF1 hits in the melanocytes. J Invest Dermatol. 2008 Apr;128(4):1050-3.
McGillicuddy LT, Fromm JA, Hollstein PE, Kubek S, Beroukhim R, De Raedt T, Johnson BW, Williams SM, Nghiemphu P, Liau LM, Cloughesy TF, Mischel PS, Parret A, Seiler J, Moldenhauer G, Scheffzek K, Stemmer-Rachamimov AO, Sawyers CL, Brennan C, Messiaen L, Mellinghoff IK, Cichowski K. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell. 2009 Jul 7;16(1):44-54.

Brems H, Park C, Maertens O, Pemov A, Messiaen L, Upadhyaya M, Claes K, Beert E, Peeters K, Mautner V, Sloan JL, Yao L, Lee CC, Sciot R, De Smet L, Legius E, Stewart DR. Glomus tumors in neurofibromatosis type 1: genetic, functional, and clinical evidence of a novel association. Cancer Res. 2009 Sep 15;69(18):7393-401
Messiaen L, Yao S, Brems H, Callens T, Sathienkijkanchai A, Denayer E, Spencer E, Arn P, Babovic-Vuksanovic D, Bay C, Bobele G, Cohen BH, Escobar L, Eunpu D, Grebe T, Greenstein R, Hachen R, Irons M, Kronn D, Lemire E, Leppig K, Lim C, McDonald M, Narayanan V, Pearn A, Pedersen R, Powell B, Shapiro LR, Skidmore D, Tegay D, Thiese H, Zackai EH, Vijzelaar R, Taniguchi K, Ayada T, Okamoto F, Yoshimura A, Parret A, Korf B, Legius E. Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome. JAMA. 2009 Nov 18;302(19):2111-8.
Hölzel M, Huang S, Koster J, Ora I, Lakeman A, Caron H, Nijkamp W, Xie J, Callens T, Asgharzadeh S, Seeger RC, Messiaen L, Versteeg R, Bernards R. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell. 2010 Jul 23;142(2):218-29.

Messiaen L, Vogt J, Bengesser K, Fu C, Mikhail F, Serra E, Garcia-Linares C, Cooper DN, Lazaro C, Kehrer-Sawatzki H. Mosaic type-1 NF1 microdeletions as a cause of both generalized and segmental neurofibromatosis type-1 (NF1). Hum Mutat. 2010 Nov 30
Messiaen, L., Vogt, J., Bengesser, K., Fu, C., Mikhail, F., Serra, E., Garcia-Linares, C., Cooper, D.N., Lazaro, C., Kehrer-Sawatzki, H. Mosaic type-1 NF1 microdeletions as a cause of both generalized and segmental neurofibromatosis type-1 (NF1) Hum Mutat. 2011;32(2):213-9  21280148 
Jouhilahti EM, Peltonen S, Callens T, Jokinen E, Heape AM, Messiaen L, Peltonen J. The devlopment of cutaneous neurofibromas. Am. J. Pathol. 2011: 178(2):500-5  21281783 
Spencer E, Davis J, Mikhail F, Fu C, Vijzelaar R, Zackai EH, Feret H, Meyn MS, Shugar A, Bellus G, Kocsis K, Kivirikko S, Poyhonen M, Messiaen L. Identification of SPRED1 deletions using RT-PCR, multiplex ligation-dependent probe amplification and quantitative PCR. Am. J. Med. Genet. A 2011, 155(6): 1352-1359.  21548021 
Wimmer, K., Callens, T., Wernstedt, A., Messiaen, L. The NF1 gene contains hotspots for L1 endonuclease-dependent de novo insertion. PLoS Genet 2011;7(11)  22125493 
Kannu, P., Nour, M., Irving, M., Xie, J., Loder, D., Lai, J., Islam, O., MacKenzie, J., Messiaen, L. Paraspinal ganglioneuroma in the proband of a large family with mild cutaneous manifestations of NF1, carrying a deep NF1 intronic mutation. Clin. Genet. 2013;83(2): 191-4  22533502 
Brems, H., Pasmant, E., Van Minkelen, R., Wimmer, K., Upadhyaya, M., Legius, E., Messiaen, L. (2013) Review and update of SPRED1 mutations causing Legius syndrome. Hum. Mutat. 33(11): 1538-46  22753041 
Stewart DR, Brems H, Gomes AG, Ruppert SL, Callens T, Williams J, Claes K, Bober MB, Hachen R, Kaban LB, Li H, Lin A, McDonald M, Melancon S, Ortenberg J, Radtke HB, Samson I, Saul RA, Shen J, Siqveland E, Toler TL, van Maarle M, Wallace M, Williams M, Legius E, Messiaen L. Jaffe-Campanacci syndrome, revisited: detailed clinical and molecular analyses determine whether patients have neurofibromatosis type 1, coincidental manifestations or a distinct disorder. 2014:Genet. Med. 16(6): 448-459  24232412 
Piotrowski A, Xie J, Liu YF, Poplawski AB, Gomes AR, Madanecki P, Fu C, Crowley MR, Crossman DK, Armstrong L, Babovic-Vuksanovic D, Bergner A, Blakeley JO, Blumenthal AL, Daniels MS, Feit H, Gardner K, Hurst S, Kobelka C, Lee C, Nagy R, Rauen KA, Slopis JM, Suwannarat P, Westman JA, Zanko A, Korf BR, Messiaen LM. (2014) Germline Loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas. Nat. Genet. 46(2): 182-187  24362817 
Kehrer-Sawatzki H, Bengesser K, Callens T, Mikhail F, Fu C, Hillmer M, Walker ME, Saal HM, Lacassie Y, Cooper DN, Messiaen L. Identification of large NF1 duplications reciprocal to NAHR-mediated type-1 NF1 deletions. Hum Mutat. 2014: 35(12): 1469-75.  25205021 
Rojnueangnit K, Xie J, Gomes A, Sharp A, Callens T, Chen Y, Liu Y, Cochran M, Abbott MA, Atkin J, Babovic-Vuksanovic D, Barnett CP, Crenshaw M, Bartholomew DW, Basel L, Bellus G, Ben-Shachar S, Bialer MG, Bick D, Blumberg B, Cortes F, David KL, Destree A, Duat-Rodriguez A, Earl D, Escobar L, Eswara M, Ezquieta B, Frayling IM, Frydman M, Gardner K, Gripp KW, Hernández-Chico C, Heyrman K, Ibrahim J, Janssens S, Keena BA, Llano-Rivas I, Leppig K, McDonald M, Misra VK, Mulbury J, Narayanan V, Orenstein N, Galvin-Parton P, Pedro H, Pivnick EK, Powell CM, Randolph L, Raskin S, Rosell J, Rubin K, Seashore M, Schaaf CP, Scheuerle A, Schultz M, Schorry E, Schnur R, Siqveland E, Tkachuk A, Tonsgard J, Upadhyaya M, Verma IC, Wallace S, Williams C, Zackai E, Zonana J, Lazaro C, Claes K, Korf B, Martin Y, Legius E, Messiaen L. High Incidence of Noonan Syndrome Features Including Short Stature and Pulmonic Stenosis in Patients carrying NF1 Missense Mutations Affecting p.Arg1809: Genotype-Phenotype Correlation. Hum Mutat. 2015 Jul 14. doi: 10.1002/humu.22832. [Epub ahead of print]  26178382 
Hsiao MC, Piotrowski A, Callens T, Fu C, Wimmer K, Claes KB, Messiaen L. (2015) Decoding NF1 Intragenic Copy-Number Variations. Am J Hum Genet.;97(2):238-49.   26189818 

the neurofibromatoses, genetic testing, mosaicism, splicing, RNA-based mutation analysis